Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T breakthroughs come with infection risks – new study aims to decode them

NCT ID NCT07713511

Not yet recruiting Knowledge-focused Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study follows adults with multiple myeloma or B-cell lymphoma who receive CAR-T cell therapy, a powerful immune treatment. Researchers track infections that occur in the first year after treatment, looking at how common they are, what causes them, and which factors raise the risk. For patients who develop fever, a rapid molecular blood test is used alongside standard methods to spot bloodstream infections faster. The goal is to improve infection management and support timely care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CAR-T cell therapy
What this could lead to
If successful, this study could help doctors better predict and quickly diagnose infections after CAR-T therapy, potentially improving patient outcomes.
What could go wrong
This is an observational study, so it won't test a new treatment. It may only identify associations, not causes, and results may not apply to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma bacterial infectious disease with sepsis cytokine release syndrome plasma cell myeloma refractory plasma cell neoplasm Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON HODGKIN LYMPHOMA BLOODSTREAM INFECTIONS CAR T CELL THERAPY REFRACTORY MULTIPLE MYELOMA RELAPSED MULTIPLE MYELOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, Italy, 40138, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.